Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 2:22 AM
Ignite Modification Date:
2025-12-26 @ 12:54 AM
NCT ID:
NCT02877134
Group ID:
EG008
Title:
Part II: Ustekinumab
Description:
Participants received Ustekinumab (tiered doses approximating 6 milligrams/kilograms (mg/kg) intravenously \[IV\]) at Week 0 (as indicated in the bullets below), followed by 90 mg SC at Weeks 8 and 16. - Ustekinumab 260 mg (weight \[less than or equal to \[\<=\] 55 kg). - Ustekinumab 390 mg (weight greater than \[\>\] 55 kg and less than or equal to \[\<=\] 85 kg). Ustekinumab 520 mg (weight \>85 kg). Participants who completed Part II Week 24 assessments and who were benefited from continued treatment, in the opinion of the investigator, were eligible to enter the Part II LTE phase at Week 24. Participants who did not enter into LTE phase at Week 24 were followed up for safety up to Week 36.
Deaths Number Affected:
0
Deaths Number At Risk:
None
Serious Number Affected:
2
Serious Number At Risk:
47
Other Number Affected:
20
Other Number At Risk:
47
Study:
NCT02877134
Results Section:
NCT02877134
Adverse Events Module:
NCT02877134